Norway· NO-ID_282FB95A-AAB5-4641-B075-807743BE81A3
Leukine
A sargramostim product containing sargramostim, registered in Norway by Partner Therapeutics. The same ATC class is registered in 11 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Sargramostim is registered in 11 of 19 countries.
Countries holding a registration under ATC L03AA09 (sargramostim), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 7 of them publish a price we can compare per daily dose
Sargramostim · ATC L03AA09
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Sargramostim
- Manufacturer
- Partner Therapeutics
- Country
- Norway (NO)
- ATC code
- L03AA09
- ATC class
- Sargramostim
- Defined daily dose
- 0.45 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
- gtin371837584354
- no_merkevare_idID_282FB95A-AAB5-4641-B075-807743BE81A3
- no_varenummer2207545 x 250
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
191 interactions on record for sargramostim.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Sargramostim · interactions on record
191 records
- 2 severe
- 189 moderate
Most severe, free to view
- CladribineL01BB04severe
- CyclophosphamideL01AA01moderate
- ChlorambucilL01AA02moderate
- MelphalanL01AA03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Sargramostim in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumImreplys 250 µgPartner Therapeutics
- CzechiaIMREPLYSPartner Therapeutics Ltd., Dublin
- FinlandImreplysPartner Therapeutics Limited
- United KingdomLeukine 250micrograms powder for solution for injection vialsImported (United States)
- IrelandImreplys 250 microgram powder for solution for injectionPartner Therapeutics Limited
- IcelandImreplysPartner Therapeutics Limited
- Japanサルグラモスチム(遺伝子組換え)ノーベルファーマ
- NetherlandsImreplys 250 microgram poeder voor oplossing voor injectiePartner Therapeutics Limited
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Imreplys
- Liechtenstein · Imreplys
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/47977b07-7450-4a09-a8de-d9e9eeb10897 GET /v1/drugs/47977b07-7450-4a09-a8de-d9e9eeb10897?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Pulver til konsentrat til injeksjons-/infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Sargramostim",
"merkevare_id": "ID_282FB95A-AAB5-4641-B075-807743BE81A3",
"name_form_strength": "Leukine pulver til konsentrat til injeksjons-/infusjonsvæske, oppløsning 250 mikrog",
"prescription_group": "C"
}See everything about sargramostim.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.